Mert Aktar - 27 May 2026 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Reporting relationship: Director
Issuer ticker: KYTX
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 16:30:02 UTC
Prior SEC filing: 02 Jun 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Samantha H. Eldredge, as Attorney-in-fact

Key filing fact

Mert Aktar filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 29 May 2026.

Key facts

This page summarizes Mert Aktar's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002040256 Primary reporting owner

Aktar Mert

Relationship: Director
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 200, EMERYVILLE
Signature: By: /s/ Samantha H. Eldredge, as Attorney-in-fact
Signature date: 29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Award

Transaction value
Shares: +5,093
Change %: +31%
Price: $0.000000^*
Shares after: 21,727
Date: 27 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +20,582
Change %
Price: $0.000000^*
Shares after: 20,582
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,582
Exercise price: $8.59
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F2

All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.